BioSpace News Archive

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to advance vaccines and therapies to market by minimizing time to production.

Surgical implant maker Xenco Medical has announced the nationwide launch of the first injection-molded titanium foam spinal implants pre-attached to disposable, composite polymer instruments, the CancelleX porous titanium lumbar interbodies. Inspired by cancellous bone, Xenco Medical’s CancelleX lumbar interbodies feature interconnected porosity throughout each implant and break new ground in the application of injection molding

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Respiratory Virus Research Panel , a robust next-generation sequencing (NGS) approach to detecting a wide rang

NextGen Healthcare, Inc., a leading provider of ambulatory-focused technology solutions, announced Nevada Eye Physicians, a comprehensive eye care facility in the Las Vegas area, is using NextGen® Enterprise with integrated telehealth capability called NextGen Virtual Visits™.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Cirmtuzumab is an in

Increased investment in bioprocessing infrastructure furthers biologics innovation and improved efficiencies in bioproduction

- Strontium89 launched; contract manufacturer now producing commercial scale quantities; sales revenue expected to be booked this quarter - $25 million in annual sales anticipated in 2022 based on the current potential market size - COVID-19 Investigational New Drug application (or similar clinical trial proposal) to regulators planned for late 2020 [30-June-2020]

GRDG Sciences, LLC (“GRDG”) announced today that their 3F Biofragrance, developed in strategic partnership with Chemia Corporation (“Chemia”), was successful at killing SARS-CoV-2, the virus causing the COVID-19 pandemic. 3F Biofragrance was designed to satisfy the goals and principles of Project Bioshield and the Open Air

Portion of funds to be invested in expanding Multikine manufacturing facility in anticipation of marketing approval

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to review the company’s second quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor rela